Two healthcare seed funds skip follow-on reserves while Neon doubles down on Science

Layout Ventures and Proximal Ventures described a first-check strategy. Neon’s Kimmy Scotti said her firm sets aside about a third of its fund for follow-ons and used a separate vehicle for a larger commitment to Science Corporation.

Author
HDM Staff
Save
Share
Illuminated HLTH lettering and event entrance arch
Event branding at the entrance to HLTH USA 2026 in Las Vegas. Photo credit: HLTH USA 2026

    Two early-stage investors explained why they leave little or no room in their main funds for a second check. A third described using a separate investment vehicle to back a company again after turning down a chance to sell. For healthcare founders, the difference can surface long after the first term sheet, when a new lead investor asks whether the existing ones will participate. The answer may reflect a decision the fund made before the founder ever walked through its door.

    Aaron Szekel, founder and partner at Layout Ventures, and Sahir Raoof, founder and managing partner at Proximal Ventures, described funds built to enter early and put their dollars to work across new companies. Kimmy Scotti, founding and managing partner at Neon, said she reserves roughly a third of her fund for follow-ons and can use a separate vehicle for a larger investment. Jonathan Machado, managing director at M² Equity Partners, moderated the Nov. 17 discussion, Building the Next Household Names in VC, at the Startup Acceleration Stage in Las Vegas.

    An early check can come with very different expectations

    Asked what proportion Layout keeps for follow-ons, Szekel answered, “Reserve zero.” He said the firm invests $200,000 to $300,000 in first institutional rounds. The check comes with help on distribution. Szekel argued that a small investor with ties to health systems, payers and life sciences companies can give a founder introductions, access to advisers and help finding talent. For a startup with a prospective hospital or pharmaceutical customer, that assistance can be put to use before a larger financing is even on the table.

    Szekel also described the ability to “sell some of your stake” if a later financing brings in buyers for existing shares. In his hypothetical example, selling a portion after a substantial increase in valuation could generate a cash distribution while retaining some ownership. The option depends on finding a buyer and being able to transfer the shares. A higher number on a financing announcement, on its own, leaves a fund’s investors waiting for cash.

    Raoof described Proximal as a “first and only check” investor in the current market. His concern was the pace of repricing. If a company raises again just weeks after the previous financing, its underlying business may have had little time to advance. He could see a case for reserving more in a market where a second investment might follow six months of progress and precede the next priced round. That puts the focus on what a company accomplished in the interval and which risks it cleared before asking for more money.

    That logic extends to where Raoof is looking for companies. He expects stronger AI models for drug discovery to put pressure on “everything that happens after drug discovery.” A better flow of candidates can send more work into translational medicine, clinical trials, manufacturing and commercialization. Proximal’s adviser reported that the firm closed a $27.5 million debut fund. The fund’s size and its interest in helping founders find initial customers make the distinction between a first check and later financing particularly relevant.

    Neon took the opportunity to buy again

    Scotti put the share Neon sets aside at “about a third of our fund.” She said a sizable follow-on can still merit its own vehicle, with a smaller contribution from the main fund. The distinction gives the firm a way to invest more in a company than it would otherwise want to put through its original pool. It also gives the people committing to that separate vehicle a specific business to evaluate.

    Her example was Science Corporation, whose $400 million Series D was reported on Nov. 17. The neurotechnology company is working to bring a retinal implant to market for people with severe vision loss. Scotti said Neon had invested in the previous round and had been offered a chance to sell shares. She described the decision to invest again this way. “We’re going to triple down.” For a firm that begins at seed or Series A, joining a round of that size required a different means of gathering the money.

    Scotti said she used the same fee and carried-interest terms for the separate vehicle as for her fund. Fees pay for managing the investment, and carried interest gives the manager a share of gains. Her example shows where those terms come into play for a second time. The manager and participating investors both need to decide how much additional exposure makes sense when an investment they already own is available at a different price.

    A first close can shape the whole fund

    Machado began with a fundraising distinction familiar to anyone who has raised capital for a company. One investor may be enough to start a company’s round. A first-time fund manager may need multiple limited partners to commit before the fund can reach its first close. A written expression of interest can feel decisive months before the money actually arrives. Machado described having expected backers drop out before his own first close.

    Raoof said people with whom he already had relationships helped him reach that first milestone. Later prospects could wait to see what he selected or defer until a final close was imminent. He found it more productive to return with a concrete development, such as a new investment the fund had won, than to ask whether a prospect had more questions about the original pitch. Scotti described a different advantage. Her anchor committed to three funds and helped hold initial investments ahead of the first close. Both arrangements show how much a new manager’s options depend on who is prepared to commit early.

    For founders, the comparable diligence happens before accepting money. Machado raised the signal a nonparticipating investor can send when a new lead is assessing a round. Szekel and Raoof gave one explanation for that absence. The vehicle may have been designed to make its contribution at the first financing. Neon’s Science investment showed that a manager with room to follow on can still need to raise a separate pool to make the next check meaningful. Asking which fund wrote the first check, what it has reserved and how it has handled later rounds can clarify what support will be available when the company next needs capital.